The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: A preliminary evaluation.
Paolo Giacomo ArduinoRoberto BroccolettiMario CarboneDavide ConrottoVeronica SciannameoAlessio GambinoMarco CabrasMarco CarrozzoSimone BaldovinoPublished in: Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology (2019)
This is the first report of the use of RTX as first line of therapy for PV patients with predominantly oral involvement. With the proposed regimen, the adverse effects have been minimized compared with classic systemic corticosteroid-centered therapy. Multi-center randomized controlled trail is however necessary.